Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
37 hedge funds and large institutions have $16.8M invested in Sorrento Therapeutics, Inc. in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 11 closing their positions.
150% more call options, than puts
Call options by funds: $15K | Put options by funds: $6K
20% less funds holding
Funds holding: 46 → 37 (-9)
27% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 15
33% less capital invested
Capital invested by funds: $25M → $16.8M (-$8.27M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
73% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$465K |
| 2 |
Renaissance Technologies
New York
|
+$315K |
| 3 |
BlackRock
New York
|
+$303K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
+$227K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$222K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.38M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$832K |
| 3 |
Goldman Sachs
New York
|
-$488K |
| 4 |
ECM
Element Capital Management
New York
|
-$380K |
| 5 |
Millennium Management
New York
|
-$260K |
SRNE Hedge Fund Activity: Q3 2017 in Review
37 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q3 2017, worth a combined $16.8M — down 33% from $25M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of SRNE and 3 opened new positions — a net loss of 8 holders — while 15 trimmed existing stakes and 11 added.
The largest buyer was Vanguard Group, adding an estimated $465K. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $3.38M sold.
- 37 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q3 2017, down from 46 in Q2 2017.
- Funds reported $16.8M of Sorrento Therapeutics, Inc. stock for Q3 2017, down 33% quarter-over-quarter.
- 3 funds opened new Sorrento Therapeutics, Inc. positions in Q3 2017 and 11 closed out, a net change of -8 holders.
- The largest Sorrento Therapeutics, Inc. buyer in Q3 2017 was Vanguard Group, an estimated $465K added.
- The largest Sorrento Therapeutics, Inc. seller in Q3 2017 was Cormorant Asset Management, an estimated $3.38M sold.
Based on aggregated 13F filings for Q3 2017.